Clinical trial
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to…
NCT00425672 · University of Washington, Other · Completed
Key facts
| NCT number | NCT00425672 |
|---|---|
| Title | ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment |
| Official title | Phase I-II Study of Denileukin Diftitox (ONTAK®) in Patients With Advanced Refractory Breast Cancer |
| Lead sponsor | University of Washington, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Male Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer |
| Intervention type | Biological, Genetic, Other |
| Interventions | ONTAK, flow cytometry, immunohistochemistry staining method, enzyme-linked immunosorbent assay, laboratory biomarker analysis, protein expression analysis |
| Enrollment | 15 |
| Start date | Sep 1, 2005 |
| Primary completion | Apr 1, 2010 |
| First posted | Jan 23, 2007 |
| Last update posted | Dec 5, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: